122 related articles for article (PubMed ID: 6488441)
21. Vidarabin-monophosphate, BCNU, VM26--an in vitro comparative study of active agents in the treatment of malignant human brain tumours.
Bogdahn U; Zapf J; Weber H; Dünisch G; Löbering HG; Martin R; Mertens HG
Br J Cancer; 1987 Feb; 55(2):153-8. PubMed ID: 2434122
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and structure-activity relationships among glycosidic derivatives of 4'-demethylepipodophyllotoxin and epipodophyllotoxin, showing VM26- and VP16-213-like activities.
Gupta RS; Chenchaiah PC; Gupta R
Anticancer Drug Des; 1987 Aug; 2(1):1-12. PubMed ID: 3449081
[TBL] [Abstract][Full Text] [Related]
23. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity.
Hayes FA; Green AA; Casper J; Cornet J; Evans WE
Cancer; 1981 Oct; 48(8):1715-8. PubMed ID: 7197189
[TBL] [Abstract][Full Text] [Related]
24. Penetration of teniposide (VM-26) into human intracerebral tumors. Preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol.
Stewart DJ; Richard MT; Hugenholtz H; Dennery J; Nundy D; Prior J; Montpetit V; Hopkins HS
J Neurooncol; 1984; 2(4):315-24. PubMed ID: 6530619
[TBL] [Abstract][Full Text] [Related]
25. VM26 (NSC-122819): a clinical study in advanced cancer of the lung and ovary.
Samson MK; Baker LH; Talley RW; Fraile RJ
Eur J Cancer (1965); 1978 Dec; 14(12):1395-9. PubMed ID: 216556
[No Abstract] [Full Text] [Related]
26. Two schedules of teniposide with or without cisplatin in advanced non-small-cell lung cancer: a randomized study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group.
Splinter TA; Sahmoud T; Festen J; van Zandwijk N; Sörenson S; Clerico M; Burghouts J; Dautzenberg B; Kho GS; Kirkpatrick A; Giaccone G
J Clin Oncol; 1996 Jan; 14(1):127-34. PubMed ID: 8558187
[TBL] [Abstract][Full Text] [Related]
27. The clinical pharmacology of VM26 and VP16-213. A brief overview.
Creaven PJ
Cancer Chemother Pharmacol; 1982; 7(2-3):133-40. PubMed ID: 7044592
[No Abstract] [Full Text] [Related]
28. Teniposide (VM26) as second-line treatment for small cell lung cancer.
Tummarello D; Guidi F; Torresi U; Dazzi C; Cellerino R
Anticancer Res; 1990; 10(2A):397-9. PubMed ID: 2161198
[TBL] [Abstract][Full Text] [Related]
29. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human cancer KB cell lines.
Matsuo K; Kohno K; Takano H; Sato S; Kiue A; Kuwano M
Cancer Res; 1990 Sep; 50(18):5819-24. PubMed ID: 2168282
[TBL] [Abstract][Full Text] [Related]
30. The clinical pharmacology of etoposide and teniposide.
Clark PI; Slevin ML
Clin Pharmacokinet; 1987 Apr; 12(4):223-52. PubMed ID: 3297462
[TBL] [Abstract][Full Text] [Related]
31. Current development of podophyllotoxins.
Canetta R; Hilgard P; Florentine S; Bedogni P; Lenaz L
Cancer Chemother Pharmacol; 1982; 7(2-3):93-8. PubMed ID: 7044596
[TBL] [Abstract][Full Text] [Related]
32. Human cytochrome P450 metabolism of teniposide and etoposide.
Relling MV; Evans R; Dass C; Desiderio DM; Nemec J
J Pharmacol Exp Ther; 1992 May; 261(2):491-6. PubMed ID: 1578365
[TBL] [Abstract][Full Text] [Related]
33. The role of histamine in doxorubicin and teniposide-induced cardiotoxicity in dog and mouse.
Gebbia N; Flandina C; Leto G; Tumminello FM; Sanguedolce R; Candiloro V; Gagliano M; Rausa L
Tumori; 1987 Jun; 73(3):279-87. PubMed ID: 3603724
[TBL] [Abstract][Full Text] [Related]
34. Phase II study of teniposide in advanced breast cancer.
Boas J; Rasmussen D; Hansen OP; Engelholm SA; Dombernowsky P
Cancer Chemother Pharmacol; 1990; 25(6):463-4. PubMed ID: 2311176
[TBL] [Abstract][Full Text] [Related]
35. Effect of cyclosporine on teniposide pharmacokinetics and pharmacodynamics in patients with renal cell cancer.
Gigante M; Sorio R; Colussi AM; Sandrin A; De Appollonia L; Galligioni E; Freschi A; Talamini R; Toffoli G; Boiocchi M
Anticancer Drugs; 1995 Jun; 6(3):479-82. PubMed ID: 7670149
[TBL] [Abstract][Full Text] [Related]
36. [A pharmacokinetic study of teniposide in intraperitoneal chemotherapy of ovarian cancer].
Cheng A; Peng Z; Hong Z
Hua Xi Yi Ke Da Xue Xue Bao; 1999 Mar; 30(1):95-8. PubMed ID: 12205938
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
38. Etoposide (VP16-213) and teniposide (VM26) comparative in vitro activities in human tumors.
Issell BF; Tihon C; Curry ME
Cancer Chemother Pharmacol; 1982; 7(2-3):113-5. PubMed ID: 7083450
[TBL] [Abstract][Full Text] [Related]
39. VM26-induced changes in hepatic intermediary metabolism of mice.
Hacker M; Roberts D
Cancer Res; 1977 Sep; 37(9):3287-92. PubMed ID: 884675
[No Abstract] [Full Text] [Related]
40. Disposition of unchanged cisplatin in patients with ovarian cancer.
Reece PA; Stafford I; Davy M; Freeman S
Clin Pharmacol Ther; 1987 Sep; 42(3):320-5. PubMed ID: 3621787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
